Board of Directors

James C. Mullen
James C. Mullen joined the Torque Board of Directors in July 2018. He is a biotech leader with more than 30 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. Previously, Mr. Mullen served as Chief Executive Officer of Patheon N.V., a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. in August 2017. Before joining Patheon, Mr. Mullen served as Chief Executive Officer and President at Biogen, one of the world’s largest biotechnology companies. Prior to being named Chief Executive Officer, Mr. Mullen held various operating positions at Biogen, including Chief Operating Officer; Vice President, International; and Vice President, Operations. Before joining Biogen, he held several manufacturing and engineering positions at SmithKline Beecham. Mr. Mullen also serves on the Board of Directors of Editas Medicine, Insulet Corporation, and Vicarius Pharma AG. He previously served on the Board of Directors of Patheon, Biogen, and PerkinElmer. He was also Chairman of the Board of Directors of the Biotechnology Innovation Organization. Mr. Mullen holds a BS in Chemical Engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.

Maykin Ho
Strategic Advisor
Maykin Ho was appointed as a strategic advisor to the Torque Board of Directors in July 2018. Dr. Ho is a member of the board of directors of Agios Pharmaceuticals, PAREXEL International, the Institute for Protein Innovation, and the Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University. She is also a venture partner at Qiming Venture Partners. Dr. Ho is a retired Partner of Goldman Sachs & Co., where she was most recently Advisory Director for Global Healthcare Investment Banking during her 23-year tenure with the firm. Previously, she was the lead biotechnology analyst and co-Head of U.S. Healthcare for Global Investment Research. Dr. Ho was ranked the First or Second Team in Biotechnology by Institutional Investor and Greenwich Associates for more than 10 years. She has also received numerous awards from The Wall Street Journal and Financial Times. Prior to joining Goldman Sachs, Dr. Ho held senior management positions in research, marketing, and business development at Dupont-Merck Pharmaceuticals and Dupont De Nemours & Company. She was a postdoctoral fellow at Harvard Medical School and a graduate of the Advanced Management Program of the Fuqua School of Business at Duke University. Dr. Ho received a PhD in Microbiology and Immunology and a BS from the State University of New York, Downstate Medical Center.

Doug Cole, MD
Lead Director
Doug Cole, MD, has served as a member of our Board of Directors since August 2015. He has been a general partner of Flagship Ventures, where he has focused on life science investments, since 2001. At Flagship, Dr. Cole has led investments in Agios Pharmaceuticals (NASDAQ:AGIO), Alvine Pharmaceuticals, Avedro, CombinatoRx (NASDAQ:ZLCS), Concert Pharmaceuticals (NASDAQ:CNCE), Editas (NASDAQ:EDIT), Quanterix , Receptos (NASDAQ:RCPT), Seventh Sense Biosystems, and Tetraphase Pharmaceuticals (NASDAQ:TTPH). He co-founded Flagship portfolio companies Ensemble Therapeutics, Permeon Biologics, Moderna Therapeutics, and Syros Pharmaceuticals. He currently serves on the Boards of Directors of Agios, Denali, Editas, Ensemble, KSQ, and Quanterix and formerly served on the Board of Directors of Avedro, AVEO Pharmaceuticals (NASDAQ: AVEO), CombinatoRx, Concert, CGI, Moderna, Morphotek, Permeon, Receptos, Resolvyx, Selecta, Seventh Sense, Syros, and Tetraphase. Dr. Cole holds a BA in English from Dartmouth College and an MD from the University of Pennsylvania School of Medicine.

John M. Dineen
John M. Dineen has served as a member of our Board of Directors since January 2016. He is an Operating Advisor to Clayton, Dublier & Rice, LLC, a private equity firm based in New York. Mr. Dineen serves as the Chairman of Healogics Corp and is a member of the board of directors of Merrimack (NASDAQ:MACK). From 1986 to 2015, Mr. Dineen served in a variety of leadership roles in the U.S., Europe, and Asia with the GE Company. During his tenure at GE, he served as President and Chief Executive Officer of GE Healthcare, Chief Executive Officer of GE Transportation, President of GE Plastics, General Manager of GE’s Power Equipment business, and General Manager of GE Appliance’s, Microwave and Air-Conditioning businesses. He holds BS degrees in Biology and Computer Science from the University of Vermont.

Bart Henderson, MBA
Bart Henderson, MBA, is a co-founder and Chief Executive Officer of Torque and has served as a member of our Board of Directors since July 2017. He was previously President and Founder of Rhythm and its subsidiary, Motus (acquired by Allergan), with responsibility for business development, finance, marketing, and manufacturing operations. Prior to that, he was Entrepreneur-in-Residence at MPM Capital; Chief Business Officer of Radius, where he was a founding employee; Head of Sales and Marketing at Vertex; Head of Business Development at Microbia (now Ironwood Pharmaceuticals); and also held marketing management positions at Amgen and Merck. Mr. Henderson received an MBA from Dartmouth’s Tuck School of Business and a BA from Amherst College.

John A. Hohneker, MD
John Hohneker, MD, has served as a member of of our Board of Directors since March 2018. He is President and CEO of Anokion, a privately held, discovery-stage biotechnology company. Prior to joining Anokion, he was President of Research and Development at FORMA Therapeutics, where he led multiple programs into clinical trials. Dr. Hohneker also held several leadership positions at Novartis, including Senior Vice President and Global Head of Development for Immunology and Dermatology. At Novartis, Dr. Hohneker played a key role in the development, approval, and commercialization of products that include Cosentyx®, Xolair®, Ilaris®, Gleevec®, Tasigna®, Zometa®, Afinitor®, and Exjade®. Prior to joining Novartis, he held positions of increasing responsibility at Glaxo Wellcome and its legacy company, Burroughs Wellcome. Dr. Hohneker served on the Board of Directors for Dimension Therapeutics prior to its acquisition by Ultragenyx Pharmaceutical (NASDAQ: RARE). He received a bachelor’s degree in Chemistry from Gettysburg College and an MD from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School, and he completed his internship and residency in internal medicine and his fellowship in medical oncology at the University of North Carolina Hospitals.

Doug Lauffenburger, PhD
Doug Lauffenburger, PhD, has served as a member of our Board of Directors since January 2016. He is the head of the Department of Biological Engineering at the Massachusetts Institute of Technology and a pioneer in applying engineering principles to biological research. His expertise spans multiple disciplines including chemical engineering, bioengineering, biotechnology process engineering, biophysics, quantitative cell and structural biology, systems biology, and applied mathematics. He has filed numerous patents, authored a key textbook on receptor biology, and published more than 200 peer-reviewed articles. Dr. Lauffenburger is a member of the National Academy of Engineering and has served on numerous bio/pharma industry scientific advisory boards including Pfizer, Astra-Zeneca, Eli Lilly, Johnson & Johnson, and Merrimack. Dr. Lauffenburger received a BS in Chemical Engineering from the University of Illinois and a PhD in Chemical Engineering from the University of Minnesota.

Back to Top